Answers are grounded in this paper and cite their sources.
Hepatitis B virus (HBV) capsid assembly modulators are a promising class of agents for chronic HBV infection. Thioureidobenzamide compound 17i exhibits potent anti-HBV activity but suffers from poor water solubility, high cytotoxicity, and limited drug-like properties. Herein, we report the design of piperazine-thioureidobenzamide derivatives via multisite occupancy and multidimensional optimization strategies. The representative compound 35a exhibited potent anti-HBV activity and low cytotoxicity in HepAD38 cells (EC50 = 0.020 μM, CC50 > 100 μM) and HLCZ01 cells (EC50 = 0.024 μM, CC50 > 100 μM). Molecular dynamics simulations revealed that 35a retained critical hydrogen bonds with Trp-102, Thr-128, and Leu-140, while forming new hydrogen bonds with Ser-106, Thr-142, and Asn-136. Multidimensional optimization endowed 35a with improved solubility, ideal LogP and high plasma stability. In HBV carrier mouse models, 35a inhibited viral replication more effectively than 17i, highlighting its potential as a promising candidate drug for further development.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: